{"nctId":"NCT00989573","briefTitle":"A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease","startDateStruct":{"date":"2009-10"},"conditions":["Crohn's Disease"],"count":191,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"OPC-6535 25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-6535"]},{"label":"OPC-6535 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-6535"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"OPC-6535","otherNames":[]},{"name":"OPC-6535","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Primary lesion in either small intestine or large intestine\n* C-reactive protein (CRP) level above the upper limit of the normal range\n* Patients who have been receiving a 5-ASA formulation (oral mesalazine) at a fixed dose of 2.25 g/day or higher (not exceeding the approved dose) and at a fixed dosing regimen\n* Patients who have not received enteral nutrition or who have been receiving enteral nutrition at a fixed intake of 1200 kcal/day or less\n\nExclusion Criteria:\n\n* Patients with an uncontrolled external fistula (including anal fistula)\n* Patients with a history of total proctocolectomy or subtotal colectomy\n* Patients with short bowel syndrome\n* Patients with an artificial anus\n* Patients with serious infectious disease (intra-abdominal abscess, etc)\n* Patients with malignant tumor\n* Female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the trial period","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement / Number of Subjects Evaluated Ã— 100) After 8 Weeks of IMP Administration","description":"Definition of clinical improvement: Total Crohn's Disease Activity Index (CDAI) score improved by at least 70 points from the baseline score or to below 150 (CDAI \\< 150: remission, CDAI \\> 450: severe disease)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"21.0","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement Rate After 4 Weeks of IMP Administration","description":"Definition of clinical improvement: CDAI score improved by at least 70 points from the baseline score or to below 150 (CDAI \\< 150: remission, CDAI \\> 450: severe disease)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"16.1","spread":null},{"groupId":"OG002","value":"28.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Rate (Number of Subjects Showing Remission / Number of Subjects Evaluated x 100) After 4 and 8 Weeks of IMP Administration","description":"Definition of remission: Total CDAI score improved to below 150","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"11.3","spread":null},{"groupId":"OG002","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-reactive Protein (CRP) Level After 4 and 8 Weeks of IMP Administration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.25"},{"groupId":"OG001","value":"-0.16","spread":"2.35"},{"groupId":"OG002","value":"0.24","spread":"1.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"1.92"},{"groupId":"OG001","value":"-0.36","spread":"2.19"},{"groupId":"OG002","value":"0.34","spread":"1.54"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":65},"commonTop":["Nausea","Headache","Crohn's disease","Nasopharyngitis","Vomiting"]}}}